drugset
drugset / Trial / NCT01244711

Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines

NCT01244711 ↗

Phase 4 Terminated 1 enrolled Weill Medical College of Cornell University AstraZeneca · collab
NaSingle-groupOpen-labelTreatment

Summary

The hypothesis of this study is that symptoms of anxiety, depression and insomnia; and indices of psychosocial function will all improve, while BZ use will decrease significantly during a twelve-week trial period of substituting quetiapine for benzodiazepines.

Timeline

Start
2008-09
Primary completion
2011-09
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Quetiapine Small molecule 300 mg —

Indications

generalized anxiety disorder major depressive disorder